Navigation Links
Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
Date:5/14/2009

- Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 a.m. PDT -

- Phase 3 CAPACITY results oral presentation, Tuesday, May 19, 3:35 p.m. PDT -

- Conference call and webcast Tuesday, May 19, 6 p.m. PDT -

BRISBANE, Calif., May 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that an oral late-breaker presentation and two poster discussion presentations related to the company's pulmonology programs will be presented at the 2009 International Conference of the American Thoracic Society (ATS) in San Diego. In addition, the company will conduct a conference call and webcast to discuss the results of its Phase 3 CAPACITY program on Tuesday, May 19 at 6:00 p.m. PDT (9:00 p.m. EDT).

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are very pleased that our Phase 3 CAPACITY program will be the subject of two significant sessions at this year's ATS meeting. Details of the CAPACITY results will be presented in a poster discussion session on the morning of Sunday, May 17. A more in-depth presentation of the efficacy and safety data from the two CAPACITY studies will be the subject of an oral late-breaker presentation on Tuesday, May 19. In addition, the results of a large study examining the predictors of mortality in patients with idiopathic pulmonary fibrosis (IPF) will be presented in a poster discussion session on Sunday, May 17. Among the independent predictors of mortality identified in the study was change in percent predicted forced vital capacity (FVC), the primary endpoint and a component of important secondary endpoints in our CAPACITY program."

The schedule of presentations at ATS related to InterMune's efforts in the research and development of new medicines for IPF are as follows:
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon reports first quarter 2009 financial results
2. YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
3. Transgenomic, Inc. Reports First Quarter 2009 Results
4. Insmed Announces First Quarter 2009 Financial Results
5. BioMS Medical Announces First quarter 2009 results
6. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
7. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
8. deCODE genetics Announces First Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
11. VIVUS Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... NY (PRWEB) May 17, 2013 ... Topical BioMedics, Inc., has been listed among nationally ... in an initiative conducted by "U.S. News" Health ... has earned the “No. 1 Pharmacists Recommended ... 17 other national OTC brands, and is the ...
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... 17, 2013 The new Public-Private Partnership ... at the association’s recent annual meeting drew praise from ... Neelie Kroes, who called the action “a huge step ... stimulant to European innovation.” , The Board of Stakeholders ... new Photonics PPP at its 29 April meeting in ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... the accelerated development of new, safe and effective ... US and around the world, will become greater ... State University and Quintiles ( www.quintiles.com ), a ... leader in managing clinical research. The ...
... potential to save tens of thousands of lives each ... at the University of Massachusetts and the Serum Institute ... results from a Phase 1 study. The recently completed ... in protective antibody levels in the serum of treated ...
... ultrafine coal slurry has been successfully tested at the ... technology offers the possibility of reducing the coal slurry ... this new technology was presented Sept. 15 at the ... Cleaning coal after it has been mined is done ...
Cached Biology Technology:Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement 2New treatment for rabies advances after successful phase 1 trial in India 2New treatment for rabies advances after successful phase 1 trial in India 3Commercial-scale test of new technology to recover coal from sludge successful 2Commercial-scale test of new technology to recover coal from sludge successful 3
(Date:5/16/2013)... a commitment to the support of underrepresented minority ... Foundation has announced the inaugural AGA Investing in ... by the National Institute of Diabetes and Digestive ... underrepresented minority students to further their research careers ... establishing this new award, AGA demonstrates its commitment ...
(Date:5/16/2013)... used ancient shorelines to predict the stability of today,s largest ... shoreline from three million years ago, for example when ... to be evidence of a high sea level due to ... many scientists to think that if the world,s largest ice ... the same in our modern, progressively warming world. , ...
(Date:5/16/2013)... May 16, 2013 The relationship between the ... has not been clear. Schizophrenia is commonly associated ... There are clues that reduced IQ may be ... example, reduced cognitive ability may precede the onset ... present in healthy relatives of people diagnosed with ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2World's biggest ice sheets likely more stable than previously believed 2Genetic risk for schizophrenia is connected to reduced IQ 2
... reporting the first use of ordinary cotton thread and ... device microscopic technology that can transport fluids for ... chips shrink room-sized diagnostic testing equipment down to the ... in medicine, environmental sensing, and other areas. Their study ...
... the ethical dilemma involved in using human embryonic stem ... In particular, they are looking for drug-like chemical compounds ... cells now obtained from human embryos. That,s the topic ... (C&EN), ACS, weekly newsmagazine. C&EN Associate Editor Sarah ...
... including international researchers with a scientist from Cardiff University, ... panda,s unusual biological traits, including its famously restricted diet. ... genome for the first time and now, the genetic ... for the endangered species. Giant pandas are ...
Cached Biology News:Giant panda genome reveals new insights into the bear's bamboo diet 2
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: